Profound Medical is a commercial-stage medical device company selling TULSA-PRO, an MRI-guided ultrasound system that ablates prostate tissue; it is FDA 510(k)-cleared, CE-marked and approved in Canada.
Profound's case rests on growing adoption of FDA-cleared TULSA-PRO after CAPTAIN's randomized functional benefit: 50% preserved both continence and erectile function at 6 months versus 24% after robotic surgery. Record orders and expanding coverage support commercialization. Cook adds a U.S. distribution channel while Profound retains disposable and service sales; the first VA installation broadens access. Revenue conversion, cash consumption and comparative cancer durability remain central uncertainties. Free.Max compatibility offers expansion potential, with U.S. clearance still being pursued.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Orders turn into growing revenue
Do order conversion and procedure demand support sustained growth as Cook adds distribution?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cook expands TULSA sales reach; revenue conversion remains central
TULSA-PRO bets on RCT functional superiority over robotic prostatectomy driving reimbursement and adoption; 3-year oncologic data will confirm or undercut the durable value claim
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers, Endocrine and bone diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.